Isotechnika chops staff, names acting CEO in restructuring

Canada's Aurinia Pharmaceuticals, formerly called Isotechnika, is shaking up its executive team and laying off staffers. The biotech says that Richard Glickman is now the acting CEO, replacing Robert Foster, who will take the CSO's job. About a third of the company's staff is being axed while it reduces the size of its offices by half. Release

Suggested Articles

Researchers are studying the retrovirus KoRV-A, which is spreading among koalas, to gain new insights into how DNA evolves.

Shionogi and Hsiri Therapeutics first joined forces last year in a licensing and R&D deal focused on tuberculosis and non-tuberculous lung infections.

The efficacy results suggest the experimental oral therapy, abrocitinib, has a shot at challenging the blockbuster biologic incumbent.